The G3 Domain of Versican Inhibits Mesenchymal Chondrogenesis Via the Epidermal Growth Factor-like Motifs
Yaou Zhang,Liu Cao,Chris Gholam Kiani,Bing L. Yang,Burton B. Yang
DOI: https://doi.org/10.1074/jbc.273.49.33054
IF: 5.485
1998-01-01
Journal of Biological Chemistry
Abstract:Versican is a highly expressed proteoglycan in zones of developing tissues. To investigate whether versican plays a role in cell differentiation, we studied its role in mesenchymal condensation and chondrogenesis. Here we report that a mini-versican gene product inhibits mesenchymal chondrogenesis but not condensation. The mini-versican-treated mesenchymal cultures form fewer, smaller cartilaginous nodules and produced lower levels of link protein and type II collagen. The versican G3 domain alone, but not G1, was sufficient to inhibit mesenchymal chondrogenesis. Deletion of two epidermal growth factor (EGF)-like motifs in the G3 domain abolished the effect of versican. The G3 domain of aggrecan, which does not contain an EGF-like motif, did not inhibit mesenchymal chondrogenesis. We also generated a chimera construct containing the two EGF-like motifs of versican and the G3 domain of aggrecan, and we observed that this chimera construct inhibited chondrogenesis to a lesser extent than did the full-length versican G3 construct. Direct transfection of mesenchymal cells with different constructs produced similar results. Furthermore, treatment with versican antisense oligonucleotides and transfection with a versican antisense construct promoted chondrogenesis. Taken together, our results strongly suggest that versican inhibits mesenchymal chondrogenesis via its EGF-like motifs. Versican is a highly expressed proteoglycan in zones of developing tissues. To investigate whether versican plays a role in cell differentiation, we studied its role in mesenchymal condensation and chondrogenesis. Here we report that a mini-versican gene product inhibits mesenchymal chondrogenesis but not condensation. The mini-versican-treated mesenchymal cultures form fewer, smaller cartilaginous nodules and produced lower levels of link protein and type II collagen. The versican G3 domain alone, but not G1, was sufficient to inhibit mesenchymal chondrogenesis. Deletion of two epidermal growth factor (EGF)-like motifs in the G3 domain abolished the effect of versican. The G3 domain of aggrecan, which does not contain an EGF-like motif, did not inhibit mesenchymal chondrogenesis. We also generated a chimera construct containing the two EGF-like motifs of versican and the G3 domain of aggrecan, and we observed that this chimera construct inhibited chondrogenesis to a lesser extent than did the full-length versican G3 construct. Direct transfection of mesenchymal cells with different constructs produced similar results. Furthermore, treatment with versican antisense oligonucleotides and transfection with a versican antisense construct promoted chondrogenesis. Taken together, our results strongly suggest that versican inhibits mesenchymal chondrogenesis via its EGF-like motifs. epidermal growth factor reverse transcriptase polymerase chain reaction Dulbecco's modified Eagle's medium polyacrylamide gel electrophoresis nitrilotriacetic acid peanut agglutinin. Versican is expressed in a variety of tissues. High concentrations are found in embryonic tissues, such as human embryonic lung (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar), the mesenchymal cell condensation area of limb buds (2Kimata K. Oike Y. Tani K. Shinomura T. Yamagata M. Uritani M. Suzuki S. J. Biol. Chem. 1986; 261: 13517-13525Abstract Full Text PDF PubMed Google Scholar, 3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar), the perinotochordal mesenchyme between the notochord and neural tube, and basement membranes facing the neuroepithelial cells of chicks (4Yamagata M. Shinomura T. Kimata K. Anat. Embryol. 1993; 187: 433-444Crossref PubMed Scopus (82) Google Scholar). It is also present in embryonic aorta, lung, cornea, and skeletal muscle (4Yamagata M. Shinomura T. Kimata K. Anat. Embryol. 1993; 187: 433-444Crossref PubMed Scopus (82) Google Scholar). In adult tissues, versican is detected in the loose connective tissue of various organs including most smooth muscles, the central and peripheral nervous systems, the luminal surface of glandular epithelia (5Bode-Lesniewska B. Dours-Zimmermann M.T. Odermattm B.F. Briner J. Heitz P.U. Zimmermann D.R. J. Histochem. Cytochem. 1996; 44: 303-312Crossref PubMed Scopus (162) Google Scholar), blood vessels (6Yao L.Y. Moody C. Schonherr E. Wight T.N. Sandell L.J. Matrix Biol. 1994; 14: 213-225Crossref PubMed Scopus (104) Google Scholar), vessels of brain tumors (7Paulus W. Baur I. Dours-Zimmermann M.T. Zimmerman D.R. J. Neuropath. Exp. Neurol. 1996; 55: 528-533Crossref PubMed Scopus (94) Google Scholar), dermis, and in the proliferative zone of the epidermis (8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar).Versican (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 9Shinomura T. Nishida Y. Ito K. Kimata K. J. Biol. Chem. 1993; 268: 14461-14469Abstract Full Text PDF PubMed Google Scholar) is a member of the large aggregating chondroitin sulfate proteoglycan family (10Margolis R.U. Margolis R.K. Methods Enzymol. 1994; 245: 105-126Crossref PubMed Scopus (88) Google Scholar), which also includes aggrecan, neurocan, and brevican. All contain G1 domains at their amino termini and G3 domains at their carboxyl termini. A varying number of chondroitin sulfate side chains are attached to a central chondroitin sulfate bearing sequence; in versican, 12–15 chondroitin sulfate side chains are covalently attached to this sequence (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 11Krusius T. Gehlsen K.R. Ruoslahti E. J. Biol. Chem. 1987; 262: 13120-13125Abstract Full Text PDF PubMed Google Scholar). This central sequence contains two alternatively spliced domains, glycosaminoglycan-α and glycosaminoglycan-β (12Dours-Zimmermann M.T. Zimmermann D.R. J. Biol. Chem. 1994; 269: 32992-32998Abstract Full Text PDF PubMed Google Scholar, 13Naso M.F. Zimmermann D.R. Iozzo R.V. J. Biol. Chem. 1994; 269: 32999-33008Abstract Full Text PDF PubMed Google Scholar, 14Naso M.F. Morgan J.L. Buchberg A.M. Siracusa L.D. Iozzo R.V. Genomics. 1995; 29: 297-300Crossref PubMed Scopus (29) Google Scholar).The functions of these proteoglycans remain elusive. Different domains may be involved in different cellular processes. The G1 domain of versican, as well as that of other members of that family, binds hyaluronan and may participate in matrix assembly and cell-cell and cell-matrix interactions. The G3 domain, consisting of lectin-like (also called carbohydrate regulatory domain), epidermal growth factor-like (EGF1-like), and complement binding protein motifs, is structurally similar to the selectin family (15Springer T.A. Lasky L.A. Nature. 1991; 349: 196-197Crossref PubMed Scopus (411) Google Scholar). But whereas selectins play a role in mediating cell adhesion, no such function has been identified for the G3 domain of versican. It is possible that the EGF-like and lectin-like motifs are involved in intercellular signaling or cell recognition processes. The chondroitin sulfate chains of versican are reported to inhibit cell adhesion (16Yamagata M. Suzuki S. Akiyama S.K. Yamada K.M. Kimata K. J. Biol. Chem. 1989; 264: 8012-8018Abstract Full Text PDF PubMed Google Scholar, 17Yamagata M. Saga S. Kato M. Bernfield M. Kimata K. J. Cell Sci. 1993; 106: 55-65Crossref PubMed Google Scholar).Thus, versican is suspected to play a role in cellular attachment, migration, and proliferation by interacting with cell surfaces and extracellular matrix molecules (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar). It has been reported that versican interferes with the attachment of cells to various extracellular matrix components such as type I collagen, fibronectin, and laminin (16Yamagata M. Suzuki S. Akiyama S.K. Yamada K.M. Kimata K. J. Biol. Chem. 1989; 264: 8012-8018Abstract Full Text PDF PubMed Google Scholar) and acts to inhibit cell adhesion (17Yamagata M. Saga S. Kato M. Bernfield M. Kimata K. J. Cell Sci. 1993; 106: 55-65Crossref PubMed Google Scholar, 18Yamagata M. Kimata K. J. Cell Sci. 1994; 107: 2581-2590Crossref PubMed Google Scholar). It may also play a role in the formation of tissues that act as barriers to migratory neural crest cells and outgrowing axons during embryonic development (19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). The expression of versican appears to be developmentally regulated in some cases. For example, during hair development, versican is not expressed until the hair follicle starts to grow (20du Cros D.L. LeBaron R.G. Couchman J.R. J. Invest. Dermatol. 1995; 105: 426-431Abstract Full Text PDF PubMed Scopus (109) Google Scholar). Versican expression intensifies with follicle maturation, reaches a maximum at the height of the growth phase, diminishes at the end of the phase, and disappears as the follicle enters the next hair cycle. Thus, versican expression is turned on and off in each cycle, and it appears that its expression correlates with cell differentiation. Furthermore, versican is transiently expressed during mesenchymal condensation. Versican is highly expressed in condensing mesenchyme, but during the transition from mesenchyme to cartilage, the expression of versican is down-regulated and finally is restricted to the periphery of the newly formed cartilage.To study the role of versican in tissue development, we introduced a mini-versican gene product into an in vitro mesenchymal condensation and chondrogenesis model, and we observed that it inhibited mesenchymal differentiation. This was further confirmed using antisense and transfection studies. Studies using versican constructs lacking the EGF-like motif indicated that this motif is responsible for the inhibiting effect.DISCUSSIONVersican is found in significant concentrations in tissues where the cells are actively proliferating, for example, embryonic tissues and the epidermal proliferative zone (3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar, 8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar, 19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). This indicates that versican may be involved in cell growth, and our previous work has indeed confirmed that versican stimulates cell proliferation (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). Since cell growth and differentiation are usually antagonistic, we hypothesized that versican would affect cell differentiation. In this study, we report that versican does inhibit mesenchymal chondrogenesis but not condensation. The inhibition is apparently mediated, at least in part, by the G3 domain of versican and specifically by the EGF-like motifs.To determine the effects of versican, we devised an in vitroassay system using chick mesenchymal cells in culture. Our findings show that such assays are sensitive and require careful calibration of mesenchymal age and cell plating density to detect the effects of versican. After extensive experimentation, we determined that limb buds harvested in stages 22–24 were optimal for our work.In the in vitro assay, cell differentiation was monitored using three separate methods. Morphological changes provided one measure of cell differentiation: as cultures differentiate, they produce characteristic "swirls" (high densities of cells and matrix) which later develop into cartilaginous nodules and increase in size over time. The second method of assessing differentiation involved histochemical techniques. Two major products of chondrocytes are aggrecan and link protein (32Stirpe N.S. Argraves W.S. Goetinck P.F. Dev. Biol. 1987; 124: 77-81Crossref PubMed Scopus (33) Google Scholar, 33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). Alcian blue, a dye that nonspecifically stains glycosaminoglycan chains, easily detects aggrecan that possesses 100–150 chondroitin sulfate and keratin sulfate side chains. Thus, staining cultures with Alcian blue allowed detection of chondrogenesis even at early stages. Third, although aggrecan is a poor choice for monitoring the onset of chondrogenesis by immunoblot analysis as it appears on SDS-PAGE as a large smear over 500 kDa, link protein is a convenient marker for chondrogenesis. Anti-link protein antibody recognizes a discrete 52-kDa protein on an immunoblot, and although link protein appears in most tissues, it is found at high concentrations only in mature cartilage (33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). We did not detect link protein in areas of cell condensation. Since type II collagen is also a major component of cartilage, we have confirmed our results by collagen staining. Results obtained using the above techniques (morphologic analysis, Alcian blue staining, and expression of link protein) were all consistent with the inhibition of chondrogenesis by the mini-versican.In our first studies of the effects of versican on chondrogenesis, we used versican gene product, manufactured by transfected COS-7 or NIH3T3 cells and secreted into their growth media (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). By using this system, however, we could not exclude the possibility that inhibitory effects of versican on differentiation were indirect. The gene product may have interacted with other proteins to produce unidentified factors that may have been secreted into the medium, causing the observed effects. To investigate if versican acts directly, we purified the mini-versican product and demonstrated that the purified product also inhibited chondrogenesis. We used a Ni-NTA affinity column to purify the mini-versican. With extensive washing, we were always able to obtain purified products with undetectable contamination stained by silver. However, the purified products were always diluted during dialysis. The products were not concentrated in order to maintain the products in its active forms. What is important in our assay is that the purified mini-versican, although at a much lower concentration compared with those expressed by COS-7 and mesenchymal cells, inhibited mesenchymal chondrogenesis. We also used transfection and antisense approaches. Results obtained from mesenchymal cell cultures transfected with versican constructs confirmed our hypothesis that the mini-versican itself inhibits differentiation. Moreover, all versican antisense oligonucleotides and versican antisense constructs also inhibited the effect of versican on chondrogenesis. We hypothesize that at the concentration of oligonucleotides used or in the presence of antisense construct, translation of versican mRNA was inhibited.Before cells can differentiate, they must first undergo condensation. The question that arises is whether versican interferes with the differentiation process by preventing condensation. To monitor condensation, PNA, which binds to the extracellular aggregates in condensed mesenchymal cultures (27Aulthouse A.L. Solursh M. Dev. Biol. 1987; 120: 377-384Crossref PubMed Scopus (92) Google Scholar), was used. Treatment with versican or versican antisense oligonucleotides had no obvious effect on the number of PNA-stained foci observed during early stages of treatment. However, we cannot rule out the possibility that mesenchymal cells isolated from stage 22–24 embryos already contain endogenous condensation signals nor that condensation was an automatic response to high culture density. Neither exogenous addition of versican gene product nor versican antisense oligonucleotides affected condensation; however, whereas the gene product also inhibited subsequent differentiation in the culture, treatment with antisense oligonucleotides and antisense construct actually seemed to enhance chondrogenesis. Given that versican stimulates cell proliferation, and versican expression must be down-regulated before chondrogenesis can proceed, it may be that exposure to the versican gene product prevented the initiation of chondrogenesis, whereas blocking expression of versican with antisense oligonucleotides actually triggered a differentiation pathway.Given, then, that versican does not function by blocking events prerequisite to differentiation, such as condensation, but seems to inhibit the differentiation process itself, we were interested in characterizing the mechanism of its activity. By treating mesenchymal cultures with the gene products of constructs expressing various domains of the versican molecule, we found in the present study that the G3 domain of versican alone can inhibit differentiation. This domain comprises three separate sections as follows: a set of epidermal growth factor-like motifs, a carbohydrate recognition sequence, and a complement-binding protein-like sequence. When cells were treated with the products of a mini-versican construct lacking the EGF-like motifs or with aggrecan G3 domain (which does not contain EGF-like motif), the culture underwent chondrogenesis, implying that the EGF-like motifs were involved in the inhibition. These results were confirmed by direct transfection of mesenchymal cells with the above constructs. Consistent with our results, a protein containing EGF-like repeats has also been reported to prevent differentiation in adipocyte precursors (29Smas C., M. Sui H.S. Cell. 1993; 73: 725-734Abstract Full Text PDF PubMed Scopus (559) Google Scholar). Nor is this inhibition directly related to the ability of EGF to stimulate proliferation: EGF's inhibition of differentiation appears to operate via a separate mechanism (34Serrero G. Lepak N. Int. J. Obes. 1996; 20 (compare): 58-64PubMed Google Scholar). In our experiments too, the inhibitory effects of versican are distinct and not directly related to its stimulatory effects, since the amount of versican gene product required to prevent differentiation was less than the amount required to stimulate mesenchymal proliferation (data not shown). It should be mentioned that the EGF-like motifs of versican are necessary for the inhibition of chondrogenesis but are by themselves not sufficient for this function since a chimeric construct containing the EGF-like motifs of versican and the G3 domain of aggrecan only partially inhibited chondrogenesis as compared with the vG3 domain construct. These results suggest that other motifs in the G3 domain are involved in the effect of versican on chondrogenesis. We are currently studying the roles of other motifs.Evidence from this study and from other studies suggests that the proteoglycan versican may play an important and complex role in cell growth and differentiation. It simulates cell proliferation, both directly, through its G1 and EGF-like subdomains, and indirectly; and it inhibits cell differentiation, an effect mediated by its EGF-like subdomains. The physiological significance of these findings remains to be determined. Versican is expressed in a variety of tissues. High concentrations are found in embryonic tissues, such as human embryonic lung (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar), the mesenchymal cell condensation area of limb buds (2Kimata K. Oike Y. Tani K. Shinomura T. Yamagata M. Uritani M. Suzuki S. J. Biol. Chem. 1986; 261: 13517-13525Abstract Full Text PDF PubMed Google Scholar, 3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar), the perinotochordal mesenchyme between the notochord and neural tube, and basement membranes facing the neuroepithelial cells of chicks (4Yamagata M. Shinomura T. Kimata K. Anat. Embryol. 1993; 187: 433-444Crossref PubMed Scopus (82) Google Scholar). It is also present in embryonic aorta, lung, cornea, and skeletal muscle (4Yamagata M. Shinomura T. Kimata K. Anat. Embryol. 1993; 187: 433-444Crossref PubMed Scopus (82) Google Scholar). In adult tissues, versican is detected in the loose connective tissue of various organs including most smooth muscles, the central and peripheral nervous systems, the luminal surface of glandular epithelia (5Bode-Lesniewska B. Dours-Zimmermann M.T. Odermattm B.F. Briner J. Heitz P.U. Zimmermann D.R. J. Histochem. Cytochem. 1996; 44: 303-312Crossref PubMed Scopus (162) Google Scholar), blood vessels (6Yao L.Y. Moody C. Schonherr E. Wight T.N. Sandell L.J. Matrix Biol. 1994; 14: 213-225Crossref PubMed Scopus (104) Google Scholar), vessels of brain tumors (7Paulus W. Baur I. Dours-Zimmermann M.T. Zimmerman D.R. J. Neuropath. Exp. Neurol. 1996; 55: 528-533Crossref PubMed Scopus (94) Google Scholar), dermis, and in the proliferative zone of the epidermis (8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar). Versican (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 9Shinomura T. Nishida Y. Ito K. Kimata K. J. Biol. Chem. 1993; 268: 14461-14469Abstract Full Text PDF PubMed Google Scholar) is a member of the large aggregating chondroitin sulfate proteoglycan family (10Margolis R.U. Margolis R.K. Methods Enzymol. 1994; 245: 105-126Crossref PubMed Scopus (88) Google Scholar), which also includes aggrecan, neurocan, and brevican. All contain G1 domains at their amino termini and G3 domains at their carboxyl termini. A varying number of chondroitin sulfate side chains are attached to a central chondroitin sulfate bearing sequence; in versican, 12–15 chondroitin sulfate side chains are covalently attached to this sequence (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 11Krusius T. Gehlsen K.R. Ruoslahti E. J. Biol. Chem. 1987; 262: 13120-13125Abstract Full Text PDF PubMed Google Scholar). This central sequence contains two alternatively spliced domains, glycosaminoglycan-α and glycosaminoglycan-β (12Dours-Zimmermann M.T. Zimmermann D.R. J. Biol. Chem. 1994; 269: 32992-32998Abstract Full Text PDF PubMed Google Scholar, 13Naso M.F. Zimmermann D.R. Iozzo R.V. J. Biol. Chem. 1994; 269: 32999-33008Abstract Full Text PDF PubMed Google Scholar, 14Naso M.F. Morgan J.L. Buchberg A.M. Siracusa L.D. Iozzo R.V. Genomics. 1995; 29: 297-300Crossref PubMed Scopus (29) Google Scholar). The functions of these proteoglycans remain elusive. Different domains may be involved in different cellular processes. The G1 domain of versican, as well as that of other members of that family, binds hyaluronan and may participate in matrix assembly and cell-cell and cell-matrix interactions. The G3 domain, consisting of lectin-like (also called carbohydrate regulatory domain), epidermal growth factor-like (EGF1-like), and complement binding protein motifs, is structurally similar to the selectin family (15Springer T.A. Lasky L.A. Nature. 1991; 349: 196-197Crossref PubMed Scopus (411) Google Scholar). But whereas selectins play a role in mediating cell adhesion, no such function has been identified for the G3 domain of versican. It is possible that the EGF-like and lectin-like motifs are involved in intercellular signaling or cell recognition processes. The chondroitin sulfate chains of versican are reported to inhibit cell adhesion (16Yamagata M. Suzuki S. Akiyama S.K. Yamada K.M. Kimata K. J. Biol. Chem. 1989; 264: 8012-8018Abstract Full Text PDF PubMed Google Scholar, 17Yamagata M. Saga S. Kato M. Bernfield M. Kimata K. J. Cell Sci. 1993; 106: 55-65Crossref PubMed Google Scholar). Thus, versican is suspected to play a role in cellular attachment, migration, and proliferation by interacting with cell surfaces and extracellular matrix molecules (1Zimmermann D.R. Ruoslahti E. EMBO J. 1989; 8: 2975-2981Crossref PubMed Scopus (499) Google Scholar, 3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar). It has been reported that versican interferes with the attachment of cells to various extracellular matrix components such as type I collagen, fibronectin, and laminin (16Yamagata M. Suzuki S. Akiyama S.K. Yamada K.M. Kimata K. J. Biol. Chem. 1989; 264: 8012-8018Abstract Full Text PDF PubMed Google Scholar) and acts to inhibit cell adhesion (17Yamagata M. Saga S. Kato M. Bernfield M. Kimata K. J. Cell Sci. 1993; 106: 55-65Crossref PubMed Google Scholar, 18Yamagata M. Kimata K. J. Cell Sci. 1994; 107: 2581-2590Crossref PubMed Google Scholar). It may also play a role in the formation of tissues that act as barriers to migratory neural crest cells and outgrowing axons during embryonic development (19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). The expression of versican appears to be developmentally regulated in some cases. For example, during hair development, versican is not expressed until the hair follicle starts to grow (20du Cros D.L. LeBaron R.G. Couchman J.R. J. Invest. Dermatol. 1995; 105: 426-431Abstract Full Text PDF PubMed Scopus (109) Google Scholar). Versican expression intensifies with follicle maturation, reaches a maximum at the height of the growth phase, diminishes at the end of the phase, and disappears as the follicle enters the next hair cycle. Thus, versican expression is turned on and off in each cycle, and it appears that its expression correlates with cell differentiation. Furthermore, versican is transiently expressed during mesenchymal condensation. Versican is highly expressed in condensing mesenchyme, but during the transition from mesenchyme to cartilage, the expression of versican is down-regulated and finally is restricted to the periphery of the newly formed cartilage. To study the role of versican in tissue development, we introduced a mini-versican gene product into an in vitro mesenchymal condensation and chondrogenesis model, and we observed that it inhibited mesenchymal differentiation. This was further confirmed using antisense and transfection studies. Studies using versican constructs lacking the EGF-like motif indicated that this motif is responsible for the inhibiting effect. DISCUSSIONVersican is found in significant concentrations in tissues where the cells are actively proliferating, for example, embryonic tissues and the epidermal proliferative zone (3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar, 8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar, 19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). This indicates that versican may be involved in cell growth, and our previous work has indeed confirmed that versican stimulates cell proliferation (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). Since cell growth and differentiation are usually antagonistic, we hypothesized that versican would affect cell differentiation. In this study, we report that versican does inhibit mesenchymal chondrogenesis but not condensation. The inhibition is apparently mediated, at least in part, by the G3 domain of versican and specifically by the EGF-like motifs.To determine the effects of versican, we devised an in vitroassay system using chick mesenchymal cells in culture. Our findings show that such assays are sensitive and require careful calibration of mesenchymal age and cell plating density to detect the effects of versican. After extensive experimentation, we determined that limb buds harvested in stages 22–24 were optimal for our work.In the in vitro assay, cell differentiation was monitored using three separate methods. Morphological changes provided one measure of cell differentiation: as cultures differentiate, they produce characteristic "swirls" (high densities of cells and matrix) which later develop into cartilaginous nodules and increase in size over time. The second method of assessing differentiation involved histochemical techniques. Two major products of chondrocytes are aggrecan and link protein (32Stirpe N.S. Argraves W.S. Goetinck P.F. Dev. Biol. 1987; 124: 77-81Crossref PubMed Scopus (33) Google Scholar, 33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). Alcian blue, a dye that nonspecifically stains glycosaminoglycan chains, easily detects aggrecan that possesses 100–150 chondroitin sulfate and keratin sulfate side chains. Thus, staining cultures with Alcian blue allowed detection of chondrogenesis even at early stages. Third, although aggrecan is a poor choice for monitoring the onset of chondrogenesis by immunoblot analysis as it appears on SDS-PAGE as a large smear over 500 kDa, link protein is a convenient marker for chondrogenesis. Anti-link protein antibody recognizes a discrete 52-kDa protein on an immunoblot, and although link protein appears in most tissues, it is found at high concentrations only in mature cartilage (33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). We did not detect link protein in areas of cell condensation. Since type II collagen is also a major component of cartilage, we have confirmed our results by collagen staining. Results obtained using the above techniques (morphologic analysis, Alcian blue staining, and expression of link protein) were all consistent with the inhibition of chondrogenesis by the mini-versican.In our first studies of the effects of versican on chondrogenesis, we used versican gene product, manufactured by transfected COS-7 or NIH3T3 cells and secreted into their growth media (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). By using this system, however, we could not exclude the possibility that inhibitory effects of versican on differentiation were indirect. The gene product may have interacted with other proteins to produce unidentified factors that may have been secreted into the medium, causing the observed effects. To investigate if versican acts directly, we purified the mini-versican product and demonstrated that the purified product also inhibited chondrogenesis. We used a Ni-NTA affinity column to purify the mini-versican. With extensive washing, we were always able to obtain purified products with undetectable contamination stained by silver. However, the purified products were always diluted during dialysis. The products were not concentrated in order to maintain the products in its active forms. What is important in our assay is that the purified mini-versican, although at a much lower concentration compared with those expressed by COS-7 and mesenchymal cells, inhibited mesenchymal chondrogenesis. We also used transfection and antisense approaches. Results obtained from mesenchymal cell cultures transfected with versican constructs confirmed our hypothesis that the mini-versican itself inhibits differentiation. Moreover, all versican antisense oligonucleotides and versican antisense constructs also inhibited the effect of versican on chondrogenesis. We hypothesize that at the concentration of oligonucleotides used or in the presence of antisense construct, translation of versican mRNA was inhibited.Before cells can differentiate, they must first undergo condensation. The question that arises is whether versican interferes with the differentiation process by preventing condensation. To monitor condensation, PNA, which binds to the extracellular aggregates in condensed mesenchymal cultures (27Aulthouse A.L. Solursh M. Dev. Biol. 1987; 120: 377-384Crossref PubMed Scopus (92) Google Scholar), was used. Treatment with versican or versican antisense oligonucleotides had no obvious effect on the number of PNA-stained foci observed during early stages of treatment. However, we cannot rule out the possibility that mesenchymal cells isolated from stage 22–24 embryos already contain endogenous condensation signals nor that condensation was an automatic response to high culture density. Neither exogenous addition of versican gene product nor versican antisense oligonucleotides affected condensation; however, whereas the gene product also inhibited subsequent differentiation in the culture, treatment with antisense oligonucleotides and antisense construct actually seemed to enhance chondrogenesis. Given that versican stimulates cell proliferation, and versican expression must be down-regulated before chondrogenesis can proceed, it may be that exposure to the versican gene product prevented the initiation of chondrogenesis, whereas blocking expression of versican with antisense oligonucleotides actually triggered a differentiation pathway.Given, then, that versican does not function by blocking events prerequisite to differentiation, such as condensation, but seems to inhibit the differentiation process itself, we were interested in characterizing the mechanism of its activity. By treating mesenchymal cultures with the gene products of constructs expressing various domains of the versican molecule, we found in the present study that the G3 domain of versican alone can inhibit differentiation. This domain comprises three separate sections as follows: a set of epidermal growth factor-like motifs, a carbohydrate recognition sequence, and a complement-binding protein-like sequence. When cells were treated with the products of a mini-versican construct lacking the EGF-like motifs or with aggrecan G3 domain (which does not contain EGF-like motif), the culture underwent chondrogenesis, implying that the EGF-like motifs were involved in the inhibition. These results were confirmed by direct transfection of mesenchymal cells with the above constructs. Consistent with our results, a protein containing EGF-like repeats has also been reported to prevent differentiation in adipocyte precursors (29Smas C., M. Sui H.S. Cell. 1993; 73: 725-734Abstract Full Text PDF PubMed Scopus (559) Google Scholar). Nor is this inhibition directly related to the ability of EGF to stimulate proliferation: EGF's inhibition of differentiation appears to operate via a separate mechanism (34Serrero G. Lepak N. Int. J. Obes. 1996; 20 (compare): 58-64PubMed Google Scholar). In our experiments too, the inhibitory effects of versican are distinct and not directly related to its stimulatory effects, since the amount of versican gene product required to prevent differentiation was less than the amount required to stimulate mesenchymal proliferation (data not shown). It should be mentioned that the EGF-like motifs of versican are necessary for the inhibition of chondrogenesis but are by themselves not sufficient for this function since a chimeric construct containing the EGF-like motifs of versican and the G3 domain of aggrecan only partially inhibited chondrogenesis as compared with the vG3 domain construct. These results suggest that other motifs in the G3 domain are involved in the effect of versican on chondrogenesis. We are currently studying the roles of other motifs.Evidence from this study and from other studies suggests that the proteoglycan versican may play an important and complex role in cell growth and differentiation. It simulates cell proliferation, both directly, through its G1 and EGF-like subdomains, and indirectly; and it inhibits cell differentiation, an effect mediated by its EGF-like subdomains. The physiological significance of these findings remains to be determined. Versican is found in significant concentrations in tissues where the cells are actively proliferating, for example, embryonic tissues and the epidermal proliferative zone (3Shinomura T. Jensen K.L. Yamagata M. Kimata K. Solursh M. Anat. Embryol. 1990; 181: 227-233Crossref PubMed Scopus (87) Google Scholar, 8Zimmermann D.R. Dours-Zimmermann M.T. Schubert M. Bruckner-Tuderman L. J. Cell Biol. 1994; 124: 817-825Crossref PubMed Scopus (211) Google Scholar, 19Landolt R.M. Vaughan L. Winterhalter K.H. Zimmermann D.R. Development. 1995; 121: 2303-2312Crossref PubMed Google Scholar). This indicates that versican may be involved in cell growth, and our previous work has indeed confirmed that versican stimulates cell proliferation (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). Since cell growth and differentiation are usually antagonistic, we hypothesized that versican would affect cell differentiation. In this study, we report that versican does inhibit mesenchymal chondrogenesis but not condensation. The inhibition is apparently mediated, at least in part, by the G3 domain of versican and specifically by the EGF-like motifs. To determine the effects of versican, we devised an in vitroassay system using chick mesenchymal cells in culture. Our findings show that such assays are sensitive and require careful calibration of mesenchymal age and cell plating density to detect the effects of versican. After extensive experimentation, we determined that limb buds harvested in stages 22–24 were optimal for our work. In the in vitro assay, cell differentiation was monitored using three separate methods. Morphological changes provided one measure of cell differentiation: as cultures differentiate, they produce characteristic "swirls" (high densities of cells and matrix) which later develop into cartilaginous nodules and increase in size over time. The second method of assessing differentiation involved histochemical techniques. Two major products of chondrocytes are aggrecan and link protein (32Stirpe N.S. Argraves W.S. Goetinck P.F. Dev. Biol. 1987; 124: 77-81Crossref PubMed Scopus (33) Google Scholar, 33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). Alcian blue, a dye that nonspecifically stains glycosaminoglycan chains, easily detects aggrecan that possesses 100–150 chondroitin sulfate and keratin sulfate side chains. Thus, staining cultures with Alcian blue allowed detection of chondrogenesis even at early stages. Third, although aggrecan is a poor choice for monitoring the onset of chondrogenesis by immunoblot analysis as it appears on SDS-PAGE as a large smear over 500 kDa, link protein is a convenient marker for chondrogenesis. Anti-link protein antibody recognizes a discrete 52-kDa protein on an immunoblot, and although link protein appears in most tissues, it is found at high concentrations only in mature cartilage (33Neame P.J. Barry F.P. Experientia (Basel). 1993; 49: 393-402Crossref PubMed Scopus (109) Google Scholar). We did not detect link protein in areas of cell condensation. Since type II collagen is also a major component of cartilage, we have confirmed our results by collagen staining. Results obtained using the above techniques (morphologic analysis, Alcian blue staining, and expression of link protein) were all consistent with the inhibition of chondrogenesis by the mini-versican. In our first studies of the effects of versican on chondrogenesis, we used versican gene product, manufactured by transfected COS-7 or NIH3T3 cells and secreted into their growth media (21Zhang Y. Cao L. Yang B.L. Yang B.B. J. Biol. Chem. 1998; 273: 21342-21351Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar). By using this system, however, we could not exclude the possibility that inhibitory effects of versican on differentiation were indirect. The gene product may have interacted with other proteins to produce unidentified factors that may have been secreted into the medium, causing the observed effects. To investigate if versican acts directly, we purified the mini-versican product and demonstrated that the purified product also inhibited chondrogenesis. We used a Ni-NTA affinity column to purify the mini-versican. With extensive washing, we were always able to obtain purified products with undetectable contamination stained by silver. However, the purified products were always diluted during dialysis. The products were not concentrated in order to maintain the products in its active forms. What is important in our assay is that the purified mini-versican, although at a much lower concentration compared with those expressed by COS-7 and mesenchymal cells, inhibited mesenchymal chondrogenesis. We also used transfection and antisense approaches. Results obtained from mesenchymal cell cultures transfected with versican constructs confirmed our hypothesis that the mini-versican itself inhibits differentiation. Moreover, all versican antisense oligonucleotides and versican antisense constructs also inhibited the effect of versican on chondrogenesis. We hypothesize that at the concentration of oligonucleotides used or in the presence of antisense construct, translation of versican mRNA was inhibited. Before cells can differentiate, they must first undergo condensation. The question that arises is whether versican interferes with the differentiation process by preventing condensation. To monitor condensation, PNA, which binds to the extracellular aggregates in condensed mesenchymal cultures (27Aulthouse A.L. Solursh M. Dev. Biol. 1987; 120: 377-384Crossref PubMed Scopus (92) Google Scholar), was used. Treatment with versican or versican antisense oligonucleotides had no obvious effect on the number of PNA-stained foci observed during early stages of treatment. However, we cannot rule out the possibility that mesenchymal cells isolated from stage 22–24 embryos already contain endogenous condensation signals nor that condensation was an automatic response to high culture density. Neither exogenous addition of versican gene product nor versican antisense oligonucleotides affected condensation; however, whereas the gene product also inhibited subsequent differentiation in the culture, treatment with antisense oligonucleotides and antisense construct actually seemed to enhance chondrogenesis. Given that versican stimulates cell proliferation, and versican expression must be down-regulated before chondrogenesis can proceed, it may be that exposure to the versican gene product prevented the initiation of chondrogenesis, whereas blocking expression of versican with antisense oligonucleotides actually triggered a differentiation pathway. Given, then, that versican does not function by blocking events prerequisite to differentiation, such as condensation, but seems to inhibit the differentiation process itself, we were interested in characterizing the mechanism of its activity. By treating mesenchymal cultures with the gene products of constructs expressing various domains of the versican molecule, we found in the present study that the G3 domain of versican alone can inhibit differentiation. This domain comprises three separate sections as follows: a set of epidermal growth factor-like motifs, a carbohydrate recognition sequence, and a complement-binding protein-like sequence. When cells were treated with the products of a mini-versican construct lacking the EGF-like motifs or with aggrecan G3 domain (which does not contain EGF-like motif), the culture underwent chondrogenesis, implying that the EGF-like motifs were involved in the inhibition. These results were confirmed by direct transfection of mesenchymal cells with the above constructs. Consistent with our results, a protein containing EGF-like repeats has also been reported to prevent differentiation in adipocyte precursors (29Smas C., M. Sui H.S. Cell. 1993; 73: 725-734Abstract Full Text PDF PubMed Scopus (559) Google Scholar). Nor is this inhibition directly related to the ability of EGF to stimulate proliferation: EGF's inhibition of differentiation appears to operate via a separate mechanism (34Serrero G. Lepak N. Int. J. Obes. 1996; 20 (compare): 58-64PubMed Google Scholar). In our experiments too, the inhibitory effects of versican are distinct and not directly related to its stimulatory effects, since the amount of versican gene product required to prevent differentiation was less than the amount required to stimulate mesenchymal proliferation (data not shown). It should be mentioned that the EGF-like motifs of versican are necessary for the inhibition of chondrogenesis but are by themselves not sufficient for this function since a chimeric construct containing the EGF-like motifs of versican and the G3 domain of aggrecan only partially inhibited chondrogenesis as compared with the vG3 domain construct. These results suggest that other motifs in the G3 domain are involved in the effect of versican on chondrogenesis. We are currently studying the roles of other motifs. Evidence from this study and from other studies suggests that the proteoglycan versican may play an important and complex role in cell growth and differentiation. It simulates cell proliferation, both directly, through its G1 and EGF-like subdomains, and indirectly; and it inhibits cell differentiation, an effect mediated by its EGF-like subdomains. The physiological significance of these findings remains to be determined. We are grateful to Dr. Paul F. Goetinck for the monoclonal antibody 4B6. We thank Dr. S. Jothy for helpful comments and Wendy Hu for technical assistance.